Tower Research Capital LLC TRC Has $634,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Tower Research Capital LLC TRC raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 903.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,265 shares of the biotechnology company's stock after buying an additional 6,541 shares during the period. Tower Research Capital LLC TRC's holdings in Blueprint Medicines were worth $634,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cerity Partners LLC acquired a new position in Blueprint Medicines during the fourth quarter valued at approximately $291,000. Empirical Asset Management LLC bought a new stake in Blueprint Medicines during the fourth quarter worth $2,348,000. Stephens Inc. AR acquired a new stake in Blueprint Medicines in the fourth quarter valued at $321,000. Bank of New York Mellon Corp grew its position in shares of Blueprint Medicines by 2.4% in the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock valued at $26,465,000 after acquiring an additional 7,101 shares during the period. Finally, KBC Group NV increased its stake in shares of Blueprint Medicines by 63.9% during the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 1,023 shares during the last quarter.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now owns 18,270 shares of the company's stock, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares of the company's stock, valued at $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded up $5.39 on Friday, reaching $104.64. 1,514,066 shares of the stock were exchanged, compared to its average volume of 772,640. The firm's 50 day moving average is $87.69 and its 200-day moving average is $93.33. The firm has a market cap of $6.69 billion, a PE ratio of -96.89 and a beta of 0.83. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a one year low of $73.04 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The business had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same period in the prior year, the business posted $1.40 EPS. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. lifted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Needham & Company LLC decreased their target price on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating on the stock in a report on Monday, April 28th. Morgan Stanley began coverage on Blueprint Medicines in a report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target for the company. Wedbush reiterated an "outperform" rating and issued a $128.00 price objective on shares of Blueprint Medicines in a report on Thursday. Finally, StockNews.com raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $124.53.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.